Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GT Biopharma (GTBP) Common Equity (2016 - 2021)

GT Biopharma (GTBP) has disclosed Common Equity for 12 consecutive years, with $31.9 million as the latest value for Q3 2021.

  • On a quarterly basis, Common Equity rose 207.05% to $31.9 million in Q3 2021 year-over-year; TTM through Sep 2021 was $31.9 million, a 207.05% increase, with the full-year FY2020 number at -$29.4 million, down 52.42% from a year prior.
  • Common Equity was $31.9 million for Q3 2021 at GT Biopharma, down from $36.3 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $521.3 million in Q4 2017 to a low of -$565.9 million in Q3 2019.
  • A 5-year average of $23.6 million and a median of -$58000.0 in 2017 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: soared 26065150.0% in 2017, then crashed 51984.91% in 2020.
  • GT Biopharma's Common Equity stood at $521.3 million in 2017, then crashed by 97.45% to $13.3 million in 2018, then tumbled by 245.05% to -$19.3 million in 2019, then plummeted by 52.42% to -$29.4 million in 2020, then surged by 208.3% to $31.9 million in 2021.
  • Per Business Quant, the three most recent readings for GTBP's Common Equity are $31.9 million (Q3 2021), $36.3 million (Q2 2021), and $24.0 million (Q1 2021).